TCI Co., Ltd. has announced the successful results of a clinical trial for its GLP-1 Formula, a natural supplement aimed at supporting weight management in adults. The trial, which involved 560 participants, demonstrated significant weight loss, positioning the formula as a potential natural alternative for those struggling with weight.
The clinical trial, conducted between October 25 and December 31, 2023, included participants aged 18 to 75. Subjects were instructed to take one sachet containing seven tablets of the GLP-1 Formula daily before lunch. The study revealed an average weight loss of 4.9 kg per participant. Furthermore, over 59.3% of participants achieved a weight loss of at least 4 kg from their baseline body weight by the end of the trial.
The GLP-1 Formula is designed to naturally enhance the secretion of GLP-1, a hormone known for its role in regulating appetite and promoting satiety. The formula utilizes a blend of natural plant extracts, probiotics, and amino acids, including phenylalanine and leucine, to stimulate GLP-1 secretion, leading to appetite suppression and weight reduction.
Expert Commentary
"Our mission is to provide innovative, effective solutions for health and wellness, and the results of this trial affirm that GLP-1 Formula could play a significant role in supporting weight management," said Chi-Fu Chiang, Head of Research and Design at TCI. "We are excited to offer a product that not only achieves impressive weight loss but also provides a natural alternative for those struggling with weight."
About TCI Co., Ltd.
TCI Co., Ltd. is a global leader in dietary supplements and cosmetics ODM with over 40 years of experience. Operating from seven production sites worldwide, including the US, Japan, China, and Taiwan, with products distributed in 65 countries. TCI's subsidiaries include TCI BIO, MBI, TCI GENE, TCI LIVING, IOPACKAGE, and PETFOOD.
